MANGOCEUTICALS, INC. COMMON STOCK (NASDAQ: MGRX)

MANGOCEUTICALS, INC. COMMON STOCK

NASDAQ: MGRX (Mangoceuticals, Inc.)

Kemas kini terakhir: 11 Nov, 12:19AM

2.32

-0.05 (-2.11%)

Tambah ke senarai pantauan

Penutupan Terdahulu	2.37
Buka	2.28
Jumlah Dagangan	58,962
Purata Dagangan (3B)	356,644
Modal Pasaran	5,861,781

Harga / Jualan (P/S)	5.45
Harga / Buku (P/B)	0.460

Julat 52 Minggu

2.10 (-9%) — 16.80 (624%)

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Health Information Services (US)	Bercampur	Menurun
	Health Information Services (Global)	Bercampur	Menurun
Stok	Mangoceuticals, Inc.	-	-

AISkor Stockmoo

1.1

Konsensus Penganalisis	0.0
Aktiviti Orang Dalam	NA
Volatiliti Harga	0.5
Purata Bergerak Teknikal	3.5
Osilator Teknikal	0.5
Purata	1.13

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
MGRX	6 M	-	-	0.460
SY	77 M	7.89%	15.21	0.230
VSEE	21 M	-	-	6.35
BFRG	19 M	-	-	4.81
VSEEW	-	-	-	-
ACONW	-	-	-	-

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men’s wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Sektor	Healthcare
Industri	Health Information Services
% Dimiliki oleh Orang Dalam	37.45%
% Dimiliki oleh Institusi	4.69%

Pemilikan

Nama	Tarikh	Syer Dipegang
Ackerman Capital Advisors, Llc	30 Sep 2024	58,227
Desjardins Global Asset Management Inc.	31 Dec 2023	0

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
19 Dec 2024	Pengumuman	Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
04 Dec 2024	Pengumuman	Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
31 Oct 2024	Pengumuman	Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
22 Oct 2024	Pengumuman	MangoRx Announces Formation of Strategy and Alternatives Committee
21 Oct 2024	Pengumuman	MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
18 Oct 2024	Pengumuman	Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
11 Oct 2024	Pengumuman	MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
03 Oct 2024	Pengumuman	MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
01 Oct 2024	Pengumuman	MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2024	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Operasi (TTM)	-1,304.61%
EPS Cair (TTM)	-5.70
Pertumbuhan Hasil Suku Tahunan (YOY)	15.50%

Jumlah Hutang/Ekuiti (D/E MRQ)	2.06%
Nisbah Semasa (MRQ)	0.380
Aliran Tunai Operasi (OCF TTM)	-5.98 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-2.16 M

Pulangan Atas Aset (ROA TTM)	-57.51%
Pulangan Atas Ekuiti (ROE TTM)	-108.44%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)